View More View Less
  • 1 Erciyes University Department of Pharmaceutical Microbiology, Faculty of Pharmacy Kayseri Turkey
  • | 2 Kayseri Education and Research Hospital Department of Pediatric Hematology Kayseri Turkey
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

The aim of this study was to investigate the effects on the immune response of levamisole alone and in conjunction with Candida albicans stimulation in human macrophage cell culture by determining the alterations in the levels of cytokine release.Levamisole treatment was performed before, during and after infecting U-937 human macrophage cells with C. albicans. In cell supernatants, interleukin (IL)-1b, IL-12, IL-18, tumour necrosis factor alpha (TNF-α) levels were measured by ELISA.In vitro levamisole treatment accompanied by C. albicans stimulation significantly increased IL-12, IL-1β and IL-18 production in macrophage cells (p < 0.05). It was observed that when administered before C. albicans infection, levamisole significantly increased IL-12 and IL-1β production in macrophage cells (p < 0.05). Another finding was that when applied to macrophage cells simultaneously with C. albicans infection, or before infection with C. albicans, levamisole suppressed the TNF-β production stimulating effect of C. albicans (p < 0.05).These results indicated that levamisole could be useful in treating patients infected with C. albicans or in protecting individuals under the risk of being infected with this pathogen. There is a need for further experimental and clinical studies on this hypothesis.

  • Yordanov, M., Dimitrova, P., Patkar, S., Falcocchio, S., Xoxi, E., Saso, L., Ivanovska, N.: Ibogaine reduces organ colonization in murine systemic and gastrointestinal Candida albicans infections. J. Med. Microbiol. 54, 647–653 (2005).

    Ivanovska N. , 'Ibogaine reduces organ colonization in murine systemic and gastrointestinal Candida albicans infections ' (2005 ) 54 J. Med. Microbiol. : 647 -653.

    • Search Google Scholar
  • Vilanova, M., Teixeira, L., Caramalho, I., Torrado, E., Marques, A., Madureira, P., Ribeiro, A., Ferreira, P., Gama, M., Demengeot, J.: Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunology 111, 334–342 (2004).

    Demengeot J. , 'Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2 ' (2004 ) 111 Immunology : 334 -342.

    • Search Google Scholar
  • Japoni, A., Mehrabani, D., Alborzi, A., Farshad, S., Hayati, M., Dehyadegari, M. A.: Effect of cyclophosphamide on the course of Candida albicans infection in normal and vaccinated mice. Saudi Med. J. 27, 46–51 (2006).

    Dehyadegari M. A. , 'Effect of cyclophosphamide on the course of Candida albicans infection in normal and vaccinated mice ' (2006 ) 27 Saudi Med. J. : 46 -51.

    • Search Google Scholar
  • Janjatovic, A. K., Lackovic, G., Bozic, F., Popovic, M., Valpotic, I.: Levamisole synergizes proliferation of intestinal IgA+ cells in weaned pigs immunized with vaccine candidate F4ac+ nonenterotoxigenic Escherichia coli strain. J. Vet. Pharmacol. Therap. 31, 328–333 (2008).

    Valpotic I. , 'Levamisole synergizes proliferation of intestinal IgA+ cells in weaned pigs immunized with vaccine candidate F4ac+ nonenterotoxigenic Escherichia coli strain ' (2008 ) 31 J. Vet. Pharmacol. Therap. : 328 -333.

    • Search Google Scholar
  • Sun, A., Wang, J. T., Chia, J. S., Chiang, C. P.: Levamisole can modulate the serum tumor necrosis factor-α level in patients with recurrent aphtous ulcerations. J. Oral Pathol. Med. 35, 111–116 (2006).

    Chiang C. P. , 'Levamisole can modulate the serum tumor necrosis factor-α level in patients with recurrent aphtous ulcerations ' (2006 ) 35 J. Oral Pathol. Med. : 111 -116.

    • Search Google Scholar
  • Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322, 352–358 (1990).

    Glick J. H. , 'Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma ' (1990 ) 322 N. Engl. J. Med. : 352 -358.

    • Search Google Scholar
  • Romani, L.: Immunity to Candida albicans: Th1, Th2 cells and beyond. Curr. Opin. Microbiol. 2, 363–367 (1999).

    Romani L. , 'Immunity to Candida albicans: Th1, Th2 cells and beyond ' (1999 ) 2 Curr. Opin. Microbiol. : 363 -367.

    • Search Google Scholar
  • Menacci, A., Cenci, E., Del Sero, G., Fé d’Ostiani, C., Mosci, P., Trinchieri, G., Adorini, L., Romani L.: IL-10 is required for development of protective Th1 responses in IL-12 deficient mice upon Candida albicans infection. J. Immunol. 161, 1708–1717 (1998).

    Romani L. , 'IL-10 is required for development of protective Th1 responses in IL-12 deficient mice upon Candida albicans infection ' (1998 ) 161 J. Immunol. : 1708 -1717.

    • Search Google Scholar
  • Indrová, M., Bieblová, J., Bubeník, J., Reinis, M.: IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int. J. Oncol. 32, 499–507 (2008).

    Reinis M. , 'IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets ' (2008 ) 32 Int. J. Oncol. : 499 -507.

    • Search Google Scholar
  • Romani, L.: Innate and adaptive immunity in Candida albicans infections and saprophtism. J. Leukocyte Biol. 68, 175–179 (2000).

    Romani L. , 'Innate and adaptive immunity in Candida albicans infections and saprophtism ' (2000 ) 68 J. Leukocyte Biol. : 175 -179.

    • Search Google Scholar
  • Argani, H., Akhtarishojaie, E.: Levamizole enhances immune responsiveness to intra-dermal and intramuscular hepatitis B vaccination in chronic hemodialysis patients. J. Immune Based Ther. Vaccines 30, 3–6 (2006).

    Akhtarishojaie E. , 'Levamizole enhances immune responsiveness to intra-dermal and intramuscular hepatitis B vaccination in chronic hemodialysis patients ' (2006 ) 30 J. Immune Based Ther. Vaccines : 3 -6.

    • Search Google Scholar
  • O’Connell, M. J., Sargent, D. J., Windschitl, H. E., Shepherd, L., Mahoney, M. R., Krook, J. E., Rayson, S., Morton, R. F., Rowland, K. M., Kugler, J. W.: Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Clin. Colorectal Cancer 6, 133–139 (2006).

    Kugler J. W. , 'Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer ' (2006 ) 6 Clin. Colorectal Cancer : 133 -139.

    • Search Google Scholar
  • Yin, J., Jin, H., Yang, F., Ding, Z., Huang, C., Zhu, Q., Wang, B.: Synergistic effects of adjuvans interferon-γ and levamisole an DNA vaccination against infection with newcastle disease virus. Viral Immunol. 20, 288–299 (2007).

    Wang B. , 'Synergistic effects of adjuvans interferon-γ and levamisole an DNA vaccination against infection with newcastle disease virus ' (2007 ) 20 Viral Immunol. : 288 -299.

    • Search Google Scholar
  • Lai, W. H., Lu, S. Y., Eng, H. L.: Levamisole aids in treatment of refractory oral candidiasis in two patients with thymoma associated with myasthenia gravis: Report of two cases. Chang Gung Med. J. 25, 606–611 (2002).

    Eng H. L. , 'Levamisole aids in treatment of refractory oral candidiasis in two patients with thymoma associated with myasthenia gravis: Report of two cases ' (2002 ) 25 Chang Gung Med. J. : 606 -611.

    • Search Google Scholar
  • Sett, S., Mishra, S. K., Siddiqui, K. A.: Avirulent mutants of Macrophomina phaseolina and Aspergillus fumigatus initiate infection in Phaseolus mungo in the presence of phaseolinone; levamisole gives protection. J. Biosci. 25, 73–80 (2000).

    Siddiqui K. A. , 'Avirulent mutants of Macrophomina phaseolina and Aspergillus fumigatus initiate infection in Phaseolus mungo in the presence of phaseolinone; levamisole gives protection ' (2000 ) 25 J. Biosci. : 73 -80.

    • Search Google Scholar
  • Kunki, A., Mortara, L., Valle, M. T., Fenoglio, D., Terranova, M. P., Megiovanni, A. M., Alessandrini, A., Li Pira, G., Mazzarello, G., Del Bono, V., Canessa, A., Bassetti, D., Manca, F.: Recognition of antigenic clusters of Candida albicans by T lymphocytes from human immunodeficiency virus-infected persons. J. Infect. Dis. 178, 488–496 (1998).

    Manca F. , 'Recognition of antigenic clusters of Candida albicans by T lymphocytes from human immunodeficiency virus-infected persons ' (1998 ) 178 J. Infect. Dis. : 488 -496.

    • Search Google Scholar
  • Szeto, C. C., Gillespie, K. M., Mathienson, P. W.: Levamisole induces interleukin-18 and shifts type1/type 2 cytokine balance. Immunology 100, 217–224 (2000).

    Mathienson P. W. , 'Levamisole induces interleukin-18 and shifts type1/type 2 cytokine balance ' (2000 ) 100 Immunology : 217 -224.

    • Search Google Scholar
  • Tomioka, H.: Adjunctive immunotherapy of mycobacterial infections. Curr. Pharm. Des. 10, 3297–3312 (2004).

    Tomioka H. , 'Adjunctive immunotherapy of mycobacterial infections ' (2004 ) 10 Curr. Pharm. Des. : 3297 -3312.

    • Search Google Scholar
  • Chen, L. Y., Lin, Y. L., Chiang, B. L.: Levamisole enhances immune response by effecting the activation and maturation of human monocyte derived dendritic cells. Clin. Exper. Immunol. 151, 174–181 (2007).

    Chiang B. L. , 'Levamisole enhances immune response by effecting the activation and maturation of human monocyte derived dendritic cells ' (2007 ) 151 Clin. Exper. Immunol. : 174 -181.

    • Search Google Scholar
  • Kimball, E. S., Craig, R., Schneider, M., Carolyn, F., Christina, C.: Levamisole causes differential cytokine expression by elicited mouse peritoneal macrophage. J. Leukocyte Biol. 52, 349–356 (1992).

    Christina C. , 'Levamisole causes differential cytokine expression by elicited mouse peritoneal macrophage ' (1992 ) 52 J. Leukocyte Biol. : 349 -356.

    • Search Google Scholar
  • Sun, A., Chia, J. S., Wang, J. T., Chiang, C. P.: Levamisole can reduce the high serum tumour necrosis factor-alpha level to a normal level in patients with erosive oral lichen planus. Clin. Exp. Dermatol. 32, 308–310 (2007).

    Chiang C. P. , 'Levamisole can reduce the high serum tumour necrosis factor-alpha level to a normal level in patients with erosive oral lichen planus ' (2007 ) 32 Clin. Exp. Dermatol. : 308 -310.

    • Search Google Scholar

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded
2020  
Total Cites 662
WoS
Journal
Impact Factor
2,048
Rank by Immunology 145/162(Q4)
Impact Factor Microbiology 118/137 (Q4)
Impact Factor 1,904
without
Journal Self Cites
5 Year 0,671
Impact Factor
Journal  0,38
Citation Indicator  
Rank by Journal  Immunology 146/174 (Q4)
Citation Indicator  Microbiology 120/142 (Q4)
Citable 42
Items
Total 40
Articles
Total 2
Reviews
Scimago 28
H-index
Scimago 0,439
Journal Rank
Scimago Immunology and Microbiology (miscellaneous) Q4
Quartile Score Medicine (miscellaneous) Q3
Scopus 438/167=2,6
Scite Score  
Scopus General Immunology and Microbiology 31/45 (Q3)
Scite Score Rank  
Scopus 0,760
SNIP
Days from  225
sumbission
to acceptance
Days from  118
acceptance
to publication
Acceptance 19%
Rate

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2021 Online subsscription: 652 EUR / 812 USD
Subscription fee 2022 Online subsscription: 662 EUR / 832 USD
Print + online subscription: 740 EUR / 930 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Publication
Programme
2021 Volume 68
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
May 2021 6 0 0
Jun 2021 1 0 0
Jul 2021 0 0 0
Aug 2021 22 0 0
Sep 2021 5 0 0
Oct 2021 1 0 0
Nov 2021 0 0 0